Skip to content

The effectiveness and safety of Ropivacaine combined with Dexmedetomidine for TAP blockage in postoperative analgesia of kidne transplatation: a prospective, randomized clinical trial

The effectiveness and safety of Ropivacaine combined with Dexmedetomidine for TAP blockage in postoperative analgesia of kidne transplatation: a prospective, randomized clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900020903
Enrollment
Unknown
Registered
2019-01-22
Start date
2014-11-01
Completion date
Unknown
Last updated
2019-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute postoperative pain

Interventions

Group C:TAP block performed with 25 ml of 0.9% saline
Group R:TAP block performed with 25 ml of 0.4% ropivacaine
Group RD:TAP block performed with 25 ml mixture solution of 0.4% ropivacaine with 1ug/kg Dexmedetomidine

Sponsors

The First Affiliated Hospital of Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients scheduled for RT under general anesthesia,within American Society of Anesthesiologists (ASA) class II and III

Exclusion criteria

Exclusion criteria: patients with addiction to opioids, long-term usage of antidepressants, antipsychotics, anticonvulsants or clonidine, patients with coagulopathy or hepatomegaly, severe cardiovascular or respiratory disease, a history of abdominal surgery, Body Mass Index (BMI) >30kg/m2, and age older than 60 or younger than 20.

Design outcomes

Primary

MeasureTime frame
morphine consumption;

Secondary

MeasureTime frame
visualized analgesic score;the degree of sedation;the incidence of complication;fentanyl consumption;

Countries

China

Contacts

Public ContactLi Yunsheng

The First Affiliated Hospital of Sun Yat-sen University

mysjz1@163.com+86 13760863235

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026